Advances in contrast agents have greatly enhanced the sensitivity of magnetic resonance imaging (MRI) techniques for early diagnosis of cancer.However, there are still problems for the traditional MRI contrast agents.T1-weighted contrast agents, such as Gd-chelates, are most commonly used on the market.However, they are often limited by the cytotoxicity and low specificity.